fashion -WSS

fashion

author：focus 2025-10-02 07:45:05 - browse：5452

This image provided by Eisai in January 2023 shows vials and packaging for their medication, Leqembi. — Illustration: Alex Hogan/STAT; Photo: Eisai via AP

Seven months after US drug regulators fully approved Biogen’s treatment for Alzheimer’s disease, only about 2,000 patients are taking the medicine nationwide, the company said Tuesday.

Biogen’s chief executive, Christopher A. Viehbacher, said as the firm released fourth-quarter earnings that he had expected the slow uptake and sees considerable demand for the medication. He told reporters that 3,800 patients with early-stage Alzheimer’s have signed up on multiple registries to receive the drug, called Leqembi, as of last month.

Before patients can get the drug, which costs $26,500-a-year, they must undergo a brain scan or a spinal tap to confirm that they have build-up of deposits of a sticky toxic protein called beta-amyloid that is a hallmark of the disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： White House launches permanent pandemic office

WSS

Organ transplantation is at a crossroads. Major reform is needed

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

Body of missing toddler recovered in Delaware River days after flood: Police

Statins may not be needed by millions of people, study suggests

As Taiwan prepares for anti

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

entertainment

fashion

hotspot

BioMarin wins approval for gene therapy to treat hemophilia A

Hyaluronic acid injections don’t help knee osteoarthritis, study finds

Medical records are filled with copy

What to know about Saharan dust affecting the US and how it can affect health

Dobbs anniversary: the lost opportunity of abortion as health care

Death toll from an explosion and collapse of a Paris building in June climbs to 3

Medicare details structure of new drug price negotiation program

The system is set up to fail children with medical complexity

Medical records are filled with copy

Study: Why relieving medical debt did not improve financial outcomes

focus

What to know about Saharan dust affecting the US and how it can affect health

Why an extreme heat and wildfire smoke combination can be so dangerous

STAT Virtual Event: ASCO Recap, Live!

7 of the most gruesome medical devices in history

Death toll from an explosion and collapse of a Paris building in June climbs to 3

Organ transplantation is at a crossroads. Major reform is needed

leisure time

focus

explore

explore